L
Latus Bio
Discover Latus’ groundbreaking gene therapy candidates, utilizing high-throughput screened AAV capsids to transform CNS disorder treatments through precision delivery
About Latus Bio
Latus Bio is a pioneering biotechnology company specializing in the development of advanced gene therapy candidates aimed at treating central nervous system (CNS) disorders. By leveraging high-throughput screening of Adeno Associated Virus (AAV) capsid variants, Latus Bio seeks to overcome traditional challenges in gene therapy, such as lack of potency and specificity, which often necessitate high doses and lead to unwanted immune responses and tissue toxicities. The company's innovative approach focuses on precision delivery, targeting specific tissues to minimize immunogenicity and toxicity, thereby improving patient outcomes.
Read full description
Latus Bio serves a diverse range of clients, including medical institutions, research organizations, and pharmaceutical companies, operating primarily in the biotechnology and healthcare markets. The business model revolves around the development and commercialization of gene therapy candidates, with revenue generated through partnerships, licensing agreements, and direct sales of their proprietary technologies.
The company's mission is to revolutionize CNS disorder treatments by providing safer and more effective gene therapies, ultimately enhancing the quality of life for patients. Latus Bio's team consists of leading scientists, clinicians, and industry professionals dedicated to advancing the field of gene therapy.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Philadelphia, United States
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 67.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Latus Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2026 | $43M | $270M | BioAdvance · Gaingels · Modi Venture Partners · DCVC Bio | ↗ |
| SERIES AOther financing | May 2024 | $54M | $216M | 8VC · DCVC Bio | ↗ |
Growth signals
Latest recorded traffic for Latus Bio is 5.4K monthly website visits, up 12.5% over the last three months. Latus Bio's team declined 3.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Series B and later1 investor entered at this stage
The Children's Hospital of Philadelphia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Latus Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Latus Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.